About the Chronic Lymphocytic Leukemia (CLL) Therapeutics Market

Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:
• Acute myeloid (or myelogenous) leukemia (AML)
• Chronic myeloid (or myelogenous) leukemia (CML)
• Acute lymphocytic (or lymphoblastic) leukemia (ALL)
• CLL

Technavio’s analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio's report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• F. Hoffman-La Roche
• AbbVie
• Teva Pharmaceuticals
• Gilead Sciences
• Novartis
• Johnson & Johnson

Other prominent vendors
• Altor BioScience
• Amgen
• Arno Therapeutics
• AstraZeneca
• Bellicum Pharmaceuticals
• Biogen
• BioLineRx
• Boston Biomedical
• Celgene
• Emergent BioSolutions
• Genzyme
• iDD biotech
• Immunomedics
• Infinity Pharmaceuticals
• Innate Pharma
• Karyopharm Therapeutics
• Ligand Pharmaceuticals
• MedImmune
• Merck Sharp & Dohme
• Molecular Templates Inc.
• MorphoSys
• Ono Pharmaceutical
• Portola Pharmaceuticals
• Regeneron Pharmaceuticals
• Sunesis Pharmaceuticals
• TG Therapeutics
• TheraMAB
• XEME Biopharma
• Xencor
• ZIOPHARM Oncology

Market driver
• Special regulatory designations
• For a full, detailed list, view our report

Market challenge
• High cost of therapy
• For a full, detailed list, view our report

Market trend
• Rise in development of combination therapies
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.